Comparison of acid inhibition attained by esomeprazole and vonoprazan with reference to CYP2C19 genotypes

Trial Profile

Comparison of acid inhibition attained by esomeprazole and vonoprazan with reference to CYP2C19 genotypes

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Esomeprazole (Primary) ; Vonoprazan (Primary)
  • Indications Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Reflux oesophagitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Dec 2015 Number of treatment arms changed from 4 to 10 as reported by University Hospital Medical Information Network - Japan record.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top